News / Blog

Today, the U.S. House of Representatives Committee on Appropriations approved the FY 2019 Department of Defense Appropriations Bill, which includes $15 million in funding for Neurofibromatosis (NF) research.

On Friday, March 23, President Donald Trump signed into law a $1.3 trillion omnibus spending bill to fund the government through September 30, 2018. After over a year of continued advocacy by the Children’s Tumor Foundation, the agreement provides $15 million in funding for the Congressionally Directed Medical Research Program – Neurofibromatosis Research Program (CDMRP-NFRP). This funding continues Congress’ long-standing support of medical research at the Department of Defense, complementary to the Children’s Tumor Foundation’s role as a leader in NF research and advocacy.

Today, the Senate is expected to begin consideration of S. 1519, the FY 2018 National Defense Authorization Act (NDAA). As reported by the Senate Armed Services Committee, S. 1519 would have negative impacts on U.S. Department of Defense medical research programs. The Children’s Tumor Foundation has actively and continuously engaged for the past months in many avenues of bipartisan advocacy to nullify these specific provisions in the legislation, working with the Foundation’s Capitol Hill allies, the Defense Health Research Consortium, and other stakeholders to ensure no impact to the Department of Defense medical research programs.

On Friday, May 5, President Donald Trump signed the $1 trillion omnibus spending bill into law. This measure, which passed both chambers of Congress with bipartisan support, funds the government through the end of September. Importantly, it provides $15 million in funding through the Congressionally Directed Medical Research Program - Neurofibromatosis Research Program (CDMRP-NFRP), which will support Children’s Tumor Foundation (CTF) work in NF research.

On Monday, May 1, House and Senate appropriators released text of a $1 trillion omnibus spending bill agreement to fund the government through the end of September. The agreement provides $15 million in funding through the Congressionally Directed Medical Research Program - Neurofibromatosis Research Program (CDMRP-NFRP).